Preclinical News and Research

RSS

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

10 Mar 2010

MCM purchases Provantis preclinical software solution

Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation has purchased the Provantis preclinical software solution.

10 Mar 2010

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

10 Mar 2010

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that new data for BMS747158, the company’s novel drug candidate in clinical development as a Positron Emission Tomography (PET) perfusion imaging agent, will be featured in an oral presentation at the American College of Cardiology 59th Annual Scientific Session taking place March 14-16, 2010 in Atlanta.

10 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

Researchers identify a new mechanism for tumor control

The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

9 Mar 2010

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.

9 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.

8 Mar 2010

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Instem, a leading provider of early drug development software solutions, announced today that Integrated Laboratory Systems (ILS) has subscribed to Provantis™ Online, enhancing their existing software systems.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

5 Mar 2010

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Humacyte, Inc. and Xcellerex, Inc. have entered into an initial strategic collaboration for Xcellerex to develop a novel manufacturing process that will enable the production of Humacyte’s lead regenerative medicine product using Xcellerex’s XDR single use bioreactor system in its FlexFactory®. Humacyte’s product is a large diameter vascular graft that is based on its innovative and proprietary platform technology for engineering human, extracellular matrix-based tissues that have properties that are similar to native tissues.

5 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Preclinical News and Research

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

MCM purchases Provantis preclinical software solution

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers identify a new mechanism for tumor control

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics